Daratumumab Not Cost-Effective for Multiple Myeloma
Researchers sought to determine whether adding daratumumab to standard care for patients with multiple myeloma was a cost-effective option.
Researchers sought to determine whether adding daratumumab to standard care for patients with multiple myeloma was a cost-effective option.
Researchers sought to determine whether adding ixazomib to treatment with lenalidomide plus dexamethasone would give a benefit to patients with newly diagnosed multiple myeloma.
Abecma is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy.
A retrospective analysis sought to determine the effect of omitting premedications and use of a rapid infusion rate on infusion-related reactions in patients receiving daratumumab for multiple myeloma.
Researchers sought to determine whether rivaroxaban may be superior to low-molecular-weight heparin for reducing all-cause mortality.
Researchers sought to determine whether cambinol would have antitumor activity in multiple myeloma cells.
A team of investigators sought to improve the rates of anticoagulation for high-risk patients after a quality improvement project that added pharmacy/hematology oversight to VTE risk assessment.
A team of investigators conducted a phase 2 trial to assess outcomes of hepatitis C virus and varicella zoster vaccination in patients with treatment-naive CLL or those on BTK inhibitor therapy.
Researchers are examining the role of platelets as drivers of inflammation, which may provide a mechanistic link with ischemia-reperfusion injury.
Researchers sought to determine whether MRD status could be a helpful prognostic tool for survival in patients with acute leukemia prior to allo-HSCT.
Please login or register first to view this content.